The integrase inhibitors market consists of drugs that
work by interfering with HIV replication by inhibiting the integrase enzyme,
which is essential for viral replication. The integrase inhibitors offer
increased potency, limited long term toxicities and higher genetic barrier to
resistance compared to other classes of anti-retrovirals.
The global
integrase inhibitors market is estimated to be valued at US$ 33.8 Bn in 2024
and is expected to exhibit a CAGR of 10 % over the forecast period 2024-2031,
as highlighted in a new report published by Coherent Market Insights.
Market key
trends:
The rising prevalence of HIV around the world has been a major driver of growth
in the integrase inhibitors market. According to UNAIDS, approximately 38
million people were living with HIV globally in 2020. Sub-Saharan Africa
remains the worst affected region, with over 85% of the global new infections
occurring here. In 2021, there were an estimated 1.5 million new infections
worldwide, along with 650 000 AIDS-related deaths. Integrase inhibitors are now
first-line treatments for HIV as they have superior efficacy and resistance
profiles compared to earlier drug classes. Their ability to durably suppress
viral replication has led to the increasing adoption of these drugs for long
term management of HIV infected patients worldwide.
Segment
Analysis
The global integrase inhibitors market is dominated by the CCR5 antagonist
sub-segment owing to its ability to block HIV from entering and infecting
immune cells. CCR5 antagonists effectively block the CCR5 co-receptor,
preventing HIV from entering cells. These drugs have demonstrated high viral
suppression rates and favorable tolerability profiles. Some of the approved
CCR5 antagonist drugs are Pfizer’s maraviroc (Selzentry) and ViiV Healthcare’s
ibalizumab (Trogarzo).
Key Takeaways
The global integrase inhibitors market is expected to witness high growth
during the forecast period of 2024-2031. Global
Integrase Inhibitors Market Size is estimated to reach a value of US$
33.8 Bn in 2024 and projected to grow at a CAGR of 10% during the forecast
period.
Regional analysis: North America dominates the global integrase inhibitors
market currently owing to the high HIV prevalence and availability of advanced
treatment options in the region. According to UNAIDS, in 2020, around 1.2
million people were living with HIV in the United States. The presence of prominent
players and high healthcare expenditure also contribute to the large share of
the North American region.
Key players operating in the integrase inhibitors market are Koninklijke
TenCate (Netherlands), Low & Bonar (UK), Fibertex Nonwovens (Denmark), Thrace
Group (Greece), Huesker (Germany), Berry Global (US), DuPont (US), Strata
Systems (US), Leggett & Platt (US), Officine Maccaferri (Italy), GSE
Environmental (US), Kaytech (South Africa), Mattex (Saudi Arabia), NAUE
(Germany), Propex Operating Company (US), Carthage Mills (US), and Asahi Kasei
Advance Corporation (Japan), among others. Pfizer's INSTI bictegravir
(Biktarvy) dominates the integrase inhibitors market.
Comments
Post a Comment